Related references
Note: Only part of the references are listed.Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats
Scott Taylor et al.
BONE (2016)
Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling
Gary Hattersley et al.
ENDOCRINOLOGY (2016)
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis A Randomized Clinical Trial
Paul D. Miller et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Monica Florio et al.
NATURE COMMUNICATIONS (2016)
Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats
Michael S. Ominsky et al.
BONE (2015)
Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Anabolic effects of PTH and the 'anabolic window'
Michael Pazianas
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2015)
Progressive Increases in Bone Mass and Bone Strength in an Ovariectomized Rat Model of Osteoporosis After 26 Weeks of Treatment With a Sclerostin Antibody
Xiaodong Li et al.
ENDOCRINOLOGY (2014)
The Sclerostin-Independent Bone Anabolic Activity of Intermittent PTH Treatment Is Mediated by T-Cell-Produced Wnt10b
Jau-Yi Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Antiresorptives Overlapping Ongoing Teriparatide Treatment Result in Additional Increases in Bone Mineral Density
Christian Muschitz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Standardized Nomenclature, Symbols, and Units for Bone Histomorphometry: A 2012 Update of the Report of the ASBMR Histomorphometry Nomenclature Committee
David W. Dempster et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial
Joy N. Tsai et al.
LANCET (2013)
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Hua Zhu Ke et al.
ENDOCRINE REVIEWS (2012)
Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: A Randomized Controlled Trial
David W. Dempster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide
S. A. Polyzos et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Anabolic and Catabolic Regimens of Human Parathyroid Hormone 1-34 Elicit Bone- and Envelope-Specific Attenuation of Skeletal Effects in Sost-Deficient Mice
Alexander G. Robling et al.
ENDOCRINOLOGY (2011)
Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice
Gang-Qing Yao et al.
JOURNAL OF BONE AND MINERAL METABOLISM (2011)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
The Waning of Teriparatide Effect on Bone Formation Markers in Postmenopausal Osteoporosis Is Associated with Increasing Serum Levels of DKK1
Davide Gatti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes
J. H. Gooi et al.
BONE (2010)
Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1-34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation
M. Sridharan et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Are Osteoclasts Needed for the Bone Anabolic Response to Parathyroid Hormone? A STUDY OF INTERMITTENT PARATHYROID HORMONE WITH DENOSUMAB OR ALENDRONATE IN KNOCK-IN MICE EXPRESSING HUMANIZED RANKL
Dominique D. Pierroz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Parathyroid Hormone (PTH)-Induced Bone Gain Is Blunted in SOST Overexpressing and Deficient Mice
Ina Kramer et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
Matthew T. Drake et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
T Lymphocytes Amplify the Anabolic Activity of Parathyroid Hormone through Wnt10b Signaling
Masakazu Terauchi et al.
CELL METABOLISM (2009)
Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Daily treatment of aged ovariectomized rats with human parathyroid hormone (1-84) for 12 months reverses bone loss and enhances trabecular and cortical bone strength
J. Fox et al.
CALCIFIED TISSUE INTERNATIONAL (2006)
Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34
DS Miao et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Effects of parathyroid hormone on Wnt signaling pathway in bone
NH Kulkarni et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2005)
Daily and cyclic parathyroid hormone in women receiving alendronate
F Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy
S Morony et al.
ENDOCRINOLOGY (2005)
SOST is a target gene for PTH in bone
H Keller et al.
BONE (2005)
Parathyroid hormone as an anabolic skeletal therapy
MR Rubin et al.
DRUGS (2005)
Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice
DS Miao et al.
ENDOCRINOLOGY (2004)
Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34)
M Kneissel et al.
BONE (2001)
Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice
S Mohan et al.
BONE (2000)
Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893
AF Stewart et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2000)
Share Paper
